16 August 2018 | News
Merck's CRISPR integration patent portfolio includes granted patents in Australia, Canada, China, Europe, Israel, Singapore and South Korea
Merck, the vibrant science and Technology Company announced that the Australian Patent Office has allowed the company's patent application for the use of paired CRISPR nickases.
Paired nickases represent a significant step in increasing safety by driving specificity through a highly flexible and efficient approach to reduce off-target effects. This improves CRISPR's ability to fix diseased genes while not affecting healthy ones.
Paired CRISPR nickase methods build on other technologies in Merck’s CRISPR patent portfolio, including CRISPR integration. Commercial organizations need Merck’s IP for CRISPR-based insertion of DNA if they want correct genetic defects in the somatic cells of gene therapy patients. Merck is licensing this patent portfolio for all fields of use.
The allowed patent application covers a foundational CRISPR strategy in which two CRISPR nickases are targeted to a common gene target and work together by nicking or cleaving opposite strands of chromosomal sequence to create a double-stranded break.
This process can optionally include an exogenous or donor sequence for insertion in the same manner as Merck's patented CRISPR integration technology. The requirement of two CRISPR binding events greatly reduces the chances of off-target cutting at other locations in the genome.
In addition to allowing a patent application on paired nickases, the Australian Patent Office recently announced the formal grant of Merck's 2017 CRISPR integration patent, following withdrawal of four independent, anonymously filed oppositions.
Merck's CRISPR integration patent portfolio includes granted patents in Australia, Canada, China, Europe, Israel, Singapore and South Korea. These CRISPR patents are directed to chromosomal integration, or cutting of the sequence of eukaryotic cells and insertion of a synthetic exogenous DNA sequence to make a desired genomic change.
Paired CRISPR nickase methods build on other technologies in Merck's CRISPR patent portfolio, including CRISPR integration. Commercial organizations need Merck's intellectual property for CRISPR-based insertion of DNA if they seek to correct genetic defects in the somatic cells of gene therapy patients. Merck is licensing this patent portfolio for all fields of use.
As a company that for the past 14 years has been highly involved in genome-editing innovation, Merck recognizes that genome editing has resulted in major advancements in biological research and medicine.
At the same time, the growing potential of genome-editing technologies has opened scientific, legal and societal concerns. As both a user and supplier of genome-editing technology, Merck supports research with genome editing under careful consideration of ethical and legal standards.
Merck has established a Bioethics Advisory Panel to provide guidance for research in which its businesses are involved, including research on or using genome editing, and has defined a clear operational position taking into account scientific and societal issues to inform promising therapeutic approaches for use in research and applications.
Merck was the first company to offer custom biomolecules for genome editing globally (TargeTron™ RNA-guided group II introns and CompoZr™ zinc finger nucleases), driving adoption of these techniques by researchers all over the world.
Merck was also the first company to manufacture arrayed CRISPR libraries covering the entire human genome, accelerating disease cures by allowing scientists to explore more questions about root causes.